RNS Number: 9016 I Indivior PLC 13 August 2019 INDIVIOR PLC. The Company announces that it received notification on August 13, 2019 that Lorna Parker, a Non-Executive Director of the Company, acquired 8,282 shares at a price of £0.603707 per share. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

The Company announces that it received notification on August 8, 2019 that Howard Pien, Chair, acquired 50,000 shares at a price of $0.746725 per share on August 7, 2019 and acquired a further 50,000 shares at the price of $0.7359 per share on August 8, 2019. The Company also announces that it received notification on August 8, 2019 that Peter Bains, a...

RNS Number: 4167 I Indivior PLC 08 August 2019 INDIVIOR PLC. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM. The Company announces that on August 8, 2019 it granted a Conditional Award over Ordinary Shares of US $0.10 each in the Company under the Indivior...

RNS Number: 1156 I Indivior PLC 06 August 2019 INDIVIOR PLC. The Company announces that it received notification on August 6, 2019 that Mark Crossley, Chief Financial and Operations Officer, acquired 63,291 shares at a price of $0.7314 per share. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 6254 H Indivior PLC 01 August 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 5461 H Indivior PLC 01 August 2019 INDIVIOR PLC- TOTAL VOTING RIGHTS AND CAPITAL. In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6. 1, the Company hereby notifies the market that as at August 1, 2019 the Company's issued share capital consisted of 730,727,164 O rdinary Shares of US $0.10 each. RNS is approved by the Financial...

RNS Number: 2814 H Indivior PLC 31 July 2019. Slough, UK, and Richmond, VA, 31 July 2019- The Board of Indivior PLC is pleased to announce the appointment of Peter Bains as an independent Non-Executive Director of the Company with effect from 1 August 2019. Peter will also be appointed as a member of the Audit and Science& Policy Committees with effect from the same date..

U.S. net revenue declined 12% primarily due to SUBOXONE ® Film share loss to generic competitors, albeit at a lower rate than suggested by historical industry analogues 1. The impact of share loss was partially offset by good underlying market growth for buprenorphine medication-assisted treatment, strong performance of the authorized generic...

RNS Number: 1952 H Indivior PLC 30 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 0632 H Indivior PLC 29 July 2019 Indivior PLC- Director's Change of Responsibilities. Indivior PLC announces that Frank Stier, Chief Manufacturing and Supply Officer, has informed the Company that he plans to retire in 2020. In light of this development, Mark Crossley, currently Chief Financial Officer, is appointed Chief Financial and Operations...

RNS Number: 7769 G Indivior PLC 25 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 7709 G Indivior PLC 25 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

Slough, UK, July 15, 2019- Indivior PLC today announced that the Court of Appeals for the Federal Circuit has affirmed the judgments of the U.S. District Court for the District of Delaware finding that Watson Laboratories Inc.; Dr. Reddy's Laboratories; and Alvogen Pine Brook, LLC failed to show that the asserted claims of U.S. Patent No. 8,603,514 related to...

Indivior (INDV) shares were up more than a quarter in early trading after the pharmaceutical group raised revenue guidance to between $670m and $720m for 2019, up from $525-$575m, while net income is expected to be between $80m and $130m, from a loss of $40m to profit of $10m (excluding exceptional items and currency). Management attributed the improved guidance to market share outperformance of its branded SUBOXONE Film. However, the opioid addiction treatment specialist remains under investigation by the US Department of Justice over offences including marketing and promotion practices, pediatric safety claims, and overprescribing of medication by certain physicians - charges it denies and is defending itself against. Sell.

Reckitt Benckiser Group is to pay up to $1.4bn in a settlement to resolve all US federal investigations into the company in relation to the sales and marketing of opioid addiction treatment Suboxone Film by its former prescription pharmaceuticals business Indivior. The company had reached agreements with the US Department of Justice and the Federal Trade Commission. Indivior was demerged from the group in 2014. Reckitt says it “acted lawfully at all times and expressly denies all allegations that it engaged in any wrongful conduct”. It believes the agreement is in the “best interests” of the company and its shareholders as it avoids “costs, uncertainty and distraction” associated with continued investigations, litigation and the potential for an indictment at a time when it is undergoing “significant transformation” and a change of chief executive. The settlement is a “non-criminal resolution,” agreed on the basis that there is no admission of any violation of law or any wrongdoing by Reckitt or any group employee. It will be funded through existing borrowing facilities and cashflow. Reckitt has already taken a $400m provision for the potential cost and will increase this to $1.5bn at its interim results. Separately, Indivior has raised its profits and revenues guidance, stating that Suboxone has lost market share at a slower than expected pace. The company now anticipates full-year net income, excluding exceptional items, of between $80m-$130m on revenues of between $670m-$720m.

RNS Number: 2715 F Indivior PLC 11 July 2019. US Government Settlement with Reckitt Benckiser Group. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985 m. Slough, UK, and Richmond, VA, 11 July 2019- Indivior PLC today announced revised expectations for FY 2019 net revenue and net income following stronger than expected H1 2019 net revenue performance. Indivior now expects FY 2019 Group net revenue to be in...

Application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 2,000,000 Ordinary Shares of US$ 0.10 each to trade on the London Stock Exchange and to be admitted to the Official List. The shares will be issued to satisfy the vesting of share awards under the Indivior U.S. Employee Stock Purchase Plan.

RNS Number: 6333 E Indivior PLC 05 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 2421 E Indivior PLC 03 July 2019 Indivior to Announce and Present Half Year 2019 Results on July 31 st. Slough, UK, and Richmond, VA, 3 July 2019- Indivior PLC today announced that it will release its half year 2019 results on July 31st at 7:00 a.m. BST. The presentation will take place at The London Stock Exchange, 10 Paternoster Square, London EC4M 7 LS..